Linperlisib ； Rituximab
Phase 1/2Recruiting 1 views this week 0 watching💤 Quiet
Interest: 39/100
39
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Relapsed/Refractory Indolent NHL
Conditions
Relapsed/Refractory Indolent NHL
Trial Timeline
Jun 1, 2025 → Feb 1, 2027
NCT ID
NCT06981988About Linperlisib ； Rituximab
Linperlisib ； Rituximab is a phase 1/2 stage product being developed by Jiangsu Hengrui Medicine for Relapsed/Refractory Indolent NHL. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06981988. Target conditions include Relapsed/Refractory Indolent NHL.
What happened to similar drugs?
0 of 10 similar drugs in Relapsed/Refractory Indolent NHL were approved
Approved (0) Terminated (1) Active (9)
🔄SHR2554; Chidamide analog tablets + SHR2554 analog tablets; ChidamideJiangsu Hengrui MedicinePhase 3
🔄Axicabtagene Ciloleucel + Platinum-containing Salvage Chemotherapy + Cyclophosphamide + FludarabineGilead SciencesPhase 3
Hype Score Breakdown
Clinical
9
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06981988 | Phase 1/2 | Recruiting |
Competing Products
20 competing products in Relapsed/Refractory Indolent NHL